medigraphic.com
ISSN 1561-302X (Print)

2022, Number 1

<< Back Next >>

Rev cubana med 2022; 61 (1)

Dipeptidyl peptidase 4 and its function against COVID-19

Poma CM, Bardales ZV

Language: Spanish
References: 33
Page: 1-9
PDF size: 255.09 Kb.


ABSTRACT

Given the appearance of a "new virus" in the of Wuhan city, China, called SARS-CoV-2, which causes the well-known severe acute respiratory syndrome (COVID-19), many scientists are trying to find a solution against the virus that has caused a pandemic. In this search, a transmembrane glycoprotein called dipeptidyl peptidase 4 or DPP-4 was found present on the surface of different types of cells and a target in MERS-Co-V infection, which opens hope by suspecting that DPP- 4 can be a target in different coronaviruses by serving as a therapeutic strategy. Added to this, there are results that find elevated DPP-4 in patients with severe complications from COVID-19, which may be a possible marker of severity. However, there is still little emphasis on the identification and association of this glycoprotein with COVID-19. To this effect, a bibliographic review was carried out on the most significant aspects of Dipeptidyl Peptidase 4 and its function against COVID-19.


REFERENCES

  1. Papadokostaki E, Tentolouris N, Liberopoulos E. COVID-19 and diabetes: What does the clinician need to know? Primary Care Diabetes. 2020[acceso: 10/11/2020];14(5):558-63. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332931/

  2. Hamid S, Mir M, Rohela G. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes and New Infections. 2020[acceso: 10/10/2020];35:100679. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171518/

  3. Solerte S, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP-4) inhibition in COVID-19. Acta Diabetológica. 2020[acceso: 11/11/2020];57(7):779-83. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32506195/

  4. Phyu Khin P, Cha S, Jun H, Lee J. A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression. Medical Hypotheses. 2020[acceso: 01/12/2020];144:110186. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427591/

  5. Devaux C, Rolain J, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology and Infection. 2020[acceso: 13/10/2020];53(3):425-35. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32414646/

  6. Barchetta I, Cavallo M, Baroni M. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications. Diabetes Research and Clinical Practice. 2020 May [cited 2020 Oct 11];163:108165. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177127/

  7. Pitocco D, Tartaglione L, Viti L, Di Leo M, Pontecorvi A, Caputo S. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?. Diabetes Research and Clinical Practice. 2020[acceso: 12/10/2020];163:108162. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32335097/

  8. Iacobellis G. COVID-19 and diabetes: Can DPP-4 inhibition play a role? Diabetes Research and Clinical Practice. 2020[acceso: 14/10/2020];162:108125. Disponible en: Disponible en: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(20)30375-2/fulltext

  9. Dalan R. Is DPP-4 inhibition a comrade or adversary in COVID-19 infection. Diabetes Research and Clinical Practice. 2020[acceso: 20/10/2021];164:108216. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235575/

  10. Morin N. Response to COVID-19 and diabetes: Can DPP-4 inhibition play a role? - GLP-1 might play one too. Diabetes Research and Clinical Practice. 2020[acceso: 28/10/2020];164:108160. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175913/

  11. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & Endocrinology. 2020[acceso: 30/11/2020];8(9):782-92. Disponible en: Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30238-2/fulltext

  12. Yadav R, Aggarwal S, Singh A. SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020[acceso: 30/11/2020];14(5):1355-60. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372253/

  13. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and other human coronaviruses. Trends in Immunology. 2020[acceso: 15/11/2020];41(5):355-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32249063/

  14. Johnson BS, Laloraya M. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization. Cytokine & Growth Factor Reviews. 2020[acceso: 22/12/2020];54:32-42. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328575/

  15. Rodríguez Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global-Travel and the 2019 novel coronavirus. Travel Medicine and Infectious Disease. 2020[acceso: 20/11/2020];33:101578. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32044389/

  16. Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020[acceso: 21/11/2020]; 551:1-9. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0042682220301720

  17. Lahiri D, Mondal R, Deb S, Bandyopadhyay D, Shome G, Sarkar S, et al. Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020[acceso: 31/12/2020];14(5):1053-60. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1871402120302320

  18. Pérez Martínez P. Resolviendo una de las piezas del puzle: COVID-19 y diabetes tipo 2. Rev Clin Esp. 2020;220(8):507-10. DOI: https://doi.org/10.1016/j.rce.2020.05.003

  19. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Research and Clinical Practice. 2020[acceso: 28/11/2020];163:108146. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151403/#:~:text=Although%20there%20is%20no%20dearth,one%20drug%20over%20the%20other

  20. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice. 2020[acceso: 20/11/2020];162:108142. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144611/

  21. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. The Lancet Diabetes & Endocrinology. 2020[acceso: 30/11/2020];8(6):546-50. Disponible en: Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30152-2/fulltext

  22. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. Journal of Infection and Public Health. 2020[acceso: 30/12/2020];13(10):1373-80. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1876034120305311

  23. Vankadari N, Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerging Microbes & Infections. 2020[acceso: 21/11/2020];9(1):601-4. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32178593/

  24. Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R, Pozzilli P. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Research and Clinical Practice. 2021[acceso: 18/11/2020];171:108444. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32946854/

  25. Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Medical Hypotheses. 2020[acceso: 31/10/2020];143:110111. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0306987720313128

  26. Wen J, Cheng Y, Ling R, Dai Y, Huang B, Huang W, et al. Antibody-dependent enhancement of coronavirus. International Journal of Infectious Diseases. 2020[acceso: 18/11/2020];100:483-9. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1201971220307311

  27. Montagnani A, Filippo P, Gnerre P, Manfellotto D. Diabetes and COVID-19: Experience from the frontline of Internal Medicine wards in Italy. Research Gate. Elsevier. 2020[acceso: 18/11/2020]. Disponible en: Disponible en: https://www.researchgate.net/publication/343044091_Diabetes_and_CoViD-19_Experience_from_the_frontline_of_Internal_Medicine_wards_in_Italy

  28. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003[acceso: 28/10/2020];58(8):686-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/12885985/

  29. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases. 2016[acceso: 28/10/2020];49:129-33. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/27352628/

  30. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020[acceso: 22/11/2020] 323(18):1715-76. Disponible en: Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2763667

  31. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? Journal of Diabetes and its Complications. 2020[acceso: 11/12/2020];34(12):107723. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1056872720304980

  32. Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: What should be considered? Diabetes Research and Clinical Practice. 2020[acceso: 20/11/2020];163:108151. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162752/

  33. Gentile S, Mambro A, Strollo F. Parallel epidemics, or nearly so: Certainties and uncertainties about SARS-CoV-2 in Italy. Diabetes Research and Clinical Practice. 2020[acceso: 31/10/2020];164:108195. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214347/




2020     |     www.medigraphic.com